The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Open accessAbstract
The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in 1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was United States Food and Drug Administration (FDA) approved. This promises to be a rapidly expanding market, as many emerging biopharmaceutical companies are developing RNA interference (RNAi)-based, and RNA-based antisense oligonucleotide therapies. However, miRNA therapeutics are noticeably absent. miRNAs are regulatory RNAs that regulate gene expression. In disease states, the expression of many miRNAs is measurably altered. The potential of miRNAs as therapies and therapeutic targets has long been discussed and in the context of a wide variety of infections and diseases. Despite the great number of studies identifying miRNAs as potential therapeutic targets, only a handful of miRNA-targeting drugs (mimics or inhibitors) have entered clinical trials. In this review, we will discuss whether the investment in finding potential miRNA therapeutic targets has yielded feasible and practicable results, the benefits and obstacles of miRNAs as therapeutic targets, and the potential future of the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. E., Horvitz, H. R., & Ruvkun, G. (2000) · Nature · doi:10.1038/35002607 · Cited by 4,981
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 2×
“This unique ability of miRNAs, to target multiple mRNAs, potentially makes miRNAs very suitable therapeutic candidates [12,125,129].”
BackgroundChen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
The MicroRNA Spectrum in 12 Body Fluids
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., How Huang, K., Jen Lee, M., Galas, D. J., & Wang, K. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147405 · Cited by 2,477
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
MicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.054 · Cited by 1,910
The Architecture of Cognitive Control in the Human Prefrontal Cortex
Koechlin, E., Ody, C., & Kouneiher, F. (2003) · Science · doi:10.1126/science.1088545 · Cited by 1,838
Identification of genes that are associated with DNA repeats in prokaryotes
Jansen, R., Embden, J. D. A. V., Gaastra, W., & Schouls, L. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02839.x · Cited by 1,802
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Jia, Q.-W., Chen, Z.-H., Ding, X.-Q., Liu, J.-Y., Ge, P.-C., An, F.-H., Li, L.-H., Wang, L.-S., Ma, W.-Z., Yang, Z.-J., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478071 · Cited by 1,691
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 1×
“Furthermore, several animal studies have concluded that modified RNA-based oligonucleotides are specific, stable and non-toxic when delivered intravenously [50,51].”
BackgroundLorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Olsen, P. H., & Ambros, V. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9523 · Cited by 1,234
The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1083 · Cited by 1,224
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Molecular Mechanisms of RNA Interference
Wilson, R. C., & Doudna, J. A. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130404 · Cited by 1,076
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Monani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 954
Suppression of non-small cell lung tumor development by the let-7 microRNA family
Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., & Jacks, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712321105 · Cited by 843
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., & Caldas, C. (2010) · RNA · doi:10.1261/rna.1947110 · Cited by 689
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0893 · Cited by 689
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Familial amyloid polyneuropathy
Planté-Bordeneuve, V., & Said, G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70246-0 · Cited by 645
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
McBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., Gilmore, B. L., Burstein, H., Peluso, R. W., Polisky, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801775105 · Cited by 607
The let-7 microRNA reduces tumor growth in mouse models of lung cancer
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., & Slack, F. J. (2008) · Cell Cycle · doi:10.4161/cc.7.6.5834 · Cited by 593
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Lal, A., Navarro, F., Maher, C. A., Maliszewski, L. E., Yan, N., O'Day, E., Chowdhury, D., Dykxhoorn, D. M., Tsai, P., Hofmann, O., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.020 · Cited by 580
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
IsomiRs – the overlooked repertoire in the dynamic microRNAome
Neilsen, C. T., Goodall, G. J., & Bracken, C. P. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.005 · Cited by 499
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Jopling, C. L., Schütz, S., & Sarnow, P. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.013 · Cited by 427
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Sharp, M. M., Chan, C. L., Lu, C. Z., Marr, M. T., Nechaev, S., Merritt, E. W., Severinov, K., Roberts, J. W., & Gross, C. A. (1999) · Genes & Development · doi:10.1101/gad.13.22.3015 · Cited by 418
Liver-specific microRNA-122: Biogenesis and function
Jopling, C. (2012) · RNA Biology · doi:10.4161/rna.18827 · Cited by 415
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387 · cited 1×
“siRNA function can be enhanced by interferon (IFN) induction, which the immune system can harness to boost apoptosis of metastatic tumour cells [84].”
BackgroundThe role of RNAi and microRNAs in animal virus replication and antiviral immunity
Umbach, J. L., & Cullen, B. R. (2009) · Genes & Development · doi:10.1101/gad.1793309 · Cited by 383
DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000931 · Cited by 374
LNA-modified oligonucleotides mediate specific inhibition of microRNA function
Ørom, U. A., Kauppinen, S., & Lund, A. H. (2006) · Gene · doi:10.1016/j.gene.2005.12.031 · Cited by 373
Wirth, B., Herz, M., Wetter, A., Moskau, S., Hahnen, E., Rudnik-Schöneborn, S., Wienker, T., & Zerres, K. (1999) · The American Journal of Human Genetics · doi:10.1086/302369 · Cited by 368
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H. M., & Prior, T. W. (2002) · Genetics in Medicine · doi:10.1097/00125817-200201000-00004 · Cited by 364
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Aartsma-Rus, A., & Krieg, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364
Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Boudreau, R. L., Martins, I., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2008.231 · Cited by 359
Activation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358
Seitz, H. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.059 · Cited by 347
Systems approaches to polypharmacology and drug discovery.
Boran, A. D. W., & Iyengar, R. (2010) · PubMed · Cited by 339
Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
Letsinger, R. L., Zhang, G. R., Sun, D. K., Ikeuchi, T., & Sarin, P. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6553 · Cited by 304
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
Robust MicroRNA Stability in Degraded RNA Preparations from Human Tissue and Cell Samples
Jung, M., Schaefer, A., Steiner, I., Kempkensteffen, C., Stephan, C., Erbersdobler, A., & Jung, K. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.141580 · Cited by 296
Gallant-Behm, C. L., Piper, J., Lynch, J. M., Seto, A. G., Hong, S. J., Mustoe, T. A., Maari, C., Pestano, L. A., Dalby, C. M., Jackson, A. L., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.007 · Cited by 278
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 271
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp185 · Cited by 267
Sharp, P. A. (1999) · Genes & Development · doi:10.1101/gad.13.2.139 · Cited by 257
How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market.
Bonneau, É., Neveu, B., Kostantin, E., Tsongalis, G. J., & Guire, V. D. (2019) · PubMed Central · Cited by 246
Evolving landscape in the management of transthyretin amyloidosis
Hawkins, P. N., Ando, Y., Dispenzeri, A., Gonzalez-Duarte, A., Adams, D., & Suhr, O. B. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1068949 · Cited by 243
Perry, C. M., & Barman Balfour, J. A. (1999) · Drugs · doi:10.2165/00003495-199957030-00010 · Cited by 243
Li, M.-J., Kim, J., Li, S., Zaia, J., Yee, J.-K., Anderson, J., Akkina, R., & Rossi, J. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.524 · Cited by 241
VandenDriessche, T., Thorrez, L., Naldini, L., Follenzi, A., Moons, L., Berneman, Z., Collen, D., & Chuah, M. K. L. (2002) · Blood · doi:10.1182/blood.v100.3.813 · Cited by 236
Worringer, K. A., Rand, T. A., Hayashi, Y., Sami, S., Takahashi, K., Tanabe, K., Narita, M., Srivastava, D., & Yamanaka, S. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.001 · Cited by 224
Telonis, A. G., Magee, R., Loher, P., Chervoneva, I., Londin, E., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 224
De Guire, V., Robitaille, R., Tétreault, N., Guérin, R., Ménard, C., Bambace, N., & Sapieha, P. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.03.015 · Cited by 221
Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA
Singh, S., Narang, A. S., & Mahato, R. I. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0608-1 · Cited by 220
Kim, Y.-K., Yeo, J., Kim, B., Ha, M., & Kim, V. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.036 · Cited by 218
Current issues of RNAi therapeutics delivery and development
Haussecker, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.056 · Cited by 217
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Bayraktar, R., & Van Roosbroeck, K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9724-7 · Cited by 216
Intra-Platform Repeatability and Inter-Platform Comparability of MicroRNA Microarray Technology
Sato, F., Tsuchiya, S., Terasawa, K., & Tsujimoto, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005540 · Cited by 216
Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
Shukla, S., Sumaria, C. S., & Pradeepkumar, P. I. (2010) · ChemMedChem · doi:10.1002/cmdc.200900444 · Cited by 210
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron
Liu, Y. P., Haasnoot, J., ter Brake, O., Berkhout, B., & Konstantinova, P. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn109 · Cited by 210
CARPENTER, S., & KARPATI, G. (1979) · Brain · doi:10.1093/brain/102.1.147 · Cited by 202
Grimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
A Direct Comparison of Anti-microRNA Oligonucleotide Potency
Lennox, K. A., & Behlke, M. A. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0156-0 · Cited by 182
Aartsma-Rus, A., Straub, V., Hemmings, R., Haas, M., Schlosser-Weber, G., Stoyanova-Beninska, V., Mercuri, E., Muntoni, F., Sepodes, B., Vroom, E., et al. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0682 · Cited by 182
MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact
Evangelatos, G., Fragoulis, G. E., Koulouri, V., & Lambrou, G. I. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102391 · Cited by 174
LEDGF Hybrids Efficiently Retarget Lentiviral Integration Into Heterochromatin
Gijsbers, R., Ronen, K., Vets, S., Malani, N., Rijck, J. D., McNeely, M., Bushman, F. D., & Debyser, Z. (2010) · Molecular Therapy · doi:10.1038/mt.2010.36 · Cited by 164
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs
Boudreau, R. L., Monteys, A. M., & Davidson, B. L. (2008) · RNA · doi:10.1261/rna.1062908 · Cited by 163
Nusinersen for the treatment of spinal muscular atrophy
Chiriboga, C. A. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1364159 · Cited by 162
Re-Engineering RNA Molecules into Therapeutic Agents
Egli, M., & Manoharan, M. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00650 · Cited by 158
Special delivery: targeted therapy with small RNAs
Peer, D., & Lieberman, J. (2011) · Gene Therapy · doi:10.1038/gt.2011.56 · Cited by 152
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers
Rawlings-Goss, R., Campbell, M. C., & Tishkoff, S. A. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-53 · Cited by 140
Design of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic Cells
Yam, P. Y., Li, S., Wu, J. C., Hu, J. X., Zaia, J. A., & Yee, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0558 · Cited by 139
Maia, L. F., Magalhães, R., Freitas, J., Taipa, R. J. F., Pires, M. M., Osório, H., Dias, D., Pessegueiro, H., Correia, M. A., & Coelho, T. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308107 · Cited by 134
Antiviral RNAi in Insects and Mammals: Parallels and Differences
Schuster, S., Miesen, P., & van Rij, R. P. (2019) · Viruses · doi:10.3390/v11050448 · Cited by 133
Antisense Oligonucleotides: The State of the Art
Aboul-Fadl, T. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054864859 · Cited by 128
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
Garba, A. O., & Mousa, S. A. (2010) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s4878 · Cited by 126
Functional miRNAs in breast cancer drug resistance
Hu, W., Tan, C., He, Y., Zhang, G., Xu, Y., & Tang, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152462 · Cited by 126
The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas
Adams, B. D., Parsons, C., & Slack, F. J. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1114102 · Cited by 121
CRISPR/Cas9 library screening for drug target discovery
Kurata, M., Yamamoto, K., Moriarity, B. S., Kitagawa, M., & Largaespada, D. A. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0376-9 · Cited by 117
Aagaard, L. A., Zhang, J., von Eije, K. J., Li, H., Sætrom, P., Amarzguioui, M., & Rossi, J. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.147 · Cited by 115
Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites
Diederichs, S., Jung, S., Rothenberg, S. M., Smolen, G. A., Mlody, B., & Haber, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800803105 · Cited by 101
Grimm, D. (2011) · Silence · doi:10.1186/1758-907x-2-8 · Cited by 100
Petrova, N. S., Chernikov, I. V., Meschaninova, M. I., Dovydenko, I. S., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1002 · Cited by 97
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins
Bauer, M., Kinkl, N., Meixner, A., Kremmer, E., Riemenschneider, M. J., Förstl, H., Gasser, T., & Ueffing, M. (2008) · Gene Therapy · doi:10.1038/gt.2008.123 · Cited by 96
VEGF siRNA Delivery System Using Arginine-Grafted Bioreducible Poly(disulfide amine)
Kim, S. H., Jeong, J. H., Kim, T., Kim, S. W., & Bull, D. A. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800161e · Cited by 94
Combinatorial RNAi Against HIV-1 Using Extended Short Hairpin RNAs
Liu, Y. P., von Eije, K. J., Schopman, N. C. T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.176 · Cited by 94
The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro
Wu, W. Y. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s8503 · Cited by 94
Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
MacDiarmid, J. A., & Brahmbhatt, H. N. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.04.008 · Cited by 94
MicroRNAs in clinical oncology: at the crossroads between promises and problems
Metias, S., Lianidou, E. S., & Yousef, G. M. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.064717 · Cited by 89
Design of extended short hairpin RNAs for HIV-1 inhibition
Liu, Y. P., Haasnoot, J., & Berkhout, B. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm596 · Cited by 86
Sonoke, S., Ueda, T., Fujiwara, K., Sato, Y., Takagaki, K., Hirabayashi, K., Ohgi, T., & Yano, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0127 · Cited by 85
miRNA in Circulating Microvesicles as Biomarkers for Age-Related Cognitive Decline
Rani, A., O’Shea, A. M., Ianov, L., Cohen, R. A., Woods, A. J., & Foster, T. C. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00323 · Cited by 84
Antisense oligonucleotides and other genetic therapies made simple
Rossor, A. M., Reilly, M. M., & Sleigh, J. N. (2018) · Practical Neurology · doi:10.1136/practneurol-2017-001764 · Cited by 77
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567326 · Cited by 76
Circulating miRNAs as Biomarker in Cancer
Andersen, G. B., & Tost, J. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_15 · Cited by 76
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 75
Rational design of immunostimulatory siRNAs.
Gantier, M., Tong, S., Behlke, M., Irving, A. T., Lappas, M., Nilsson, U., Latz, E., McMillan, N., & Williams, B. (2010) · Molecular Therapy · doi:10.1038/mt.2010.4 · Cited by 72
microRNA-guided diagnostics in clinical samples
Gustafson, D., Tyryshkin, K., & Renwick, N. M. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.07.002 · Cited by 72
Validated MicroRNA Target Databases: An Evaluation
Lee, Y. J., Kim, V., Muth, D. C., & Witwer, K. W. (2015) · Drug Development Research · doi:10.1002/ddr.21278 · Cited by 69
Non-coding RNAs: the cancer genome dark matter that matters!
Ling, H. Y., Girnita, L., Buda, O., & Călin, G. A. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0740 · Cited by 69
Grillone, L. R., & Lanz, R. (2001) · Drugs of today · doi:10.1358/dot.2001.37.4.620590 · Cited by 69
DNA Vaccines: Regulatory Considerations and Safety Aspects
Myhr, A. I. (2016) · Current Issues in Molecular Biology · doi:10.21775/cimb.022.079 · Cited by 67
Web-based NGS data analysis using miRMaster: a large-scale meta-analysis of human miRNAs
Fehlmann, T., Backes, C., Kahraman, M., Haas, J., Ludwig, N., Posch, A. E., Würstle, M. L., Hübenthal, M., Franke, A., Meder, B., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx595 · Cited by 65
Rissin, D. M., López‐Longarela, B., Pernagallo, S., Ilyine, H., Vliegenthart, A. D. B., Dear, J. W., Díaz‐Mochon, J. J., & Duffy, D. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179669 · Cited by 64
Unwalla, H. J., Li, H.-T., Bahner, I., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1863-1873.2006 · Cited by 63
Bottleneck limitations for microRNA-based therapeutics from bench to the bedside
Chen, Y., Zhao, H., Tan, Z., Zhang, C., & Fu, X. (2015) · Die Pharmazie · doi:10.31083/ph.2015.4774 · Cited by 59
Oligonucleotide Drugs for Transthyretin Amyloidosis
Buxbaum, J. N. (2018) · New England Journal of Medicine · doi:10.1056/nejme1805499 · Cited by 59
Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
Bajan, S., & Hutvágner, G. (2014) · MicroRNA · doi:10.2174/2211536602666140110234046 · Cited by 56
Self-citationCirculating microRNA biomarkers for lung cancer detection in Western populations
Yu, H., Guan, Z., Ćuk, K., Brenner, H., & Zhang, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1782 · Cited by 56
Ligtenberg, M. A., de Coaña, Y. P., Shmushkovich, T., Yoshimoto, Y., Truxová, I., Yang, Y., Betancur-Boissel, M., Eliseev, A. V., Wolfson, A. D., & Kiessling, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.015 · Cited by 54
RNA Biology Provides New Therapeutic Targets for Human Disease
Harries, L. W. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00205 · Cited by 53
Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice
Beer, S., Bellovin, D. I., Lee, J. S., Komatsubara, K. M., Wang, L. S., Koh, H., Börner, K., Storm, T. A., Davis, C. R., Kay, M. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.222 · Cited by 51
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis
Singh, A. N., Bhattacharyya, N., Srivastava, A., Pruett, N. D., Ripley, R. T., Schrump, D. S., & Hoang, C. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.020 · Cited by 49
MicroRNAs in acute pancreatitis: From pathogenesis to novel diagnosis and therapy
Yang, Y., Huang, Q., Luo, C., Wen, Y., Liu, R., Sun, H., & Tang, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29212 · Cited by 49
Leclercq, M., Diallo, A. B., & Blanchette, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1085 · Cited by 41
miRNA Profiling for Early Detection and Treatment of Duchenne Muscular Dystrophy
Hrach, H., & Mangone, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184638 · Cited by 40
Gene therapeutic strategies for neurodegenerative diseases.
Baekelandt, V., Strooper, B. D., Nuttin, B., & Debyser, Z. (2000) · PubMed · Cited by 40
Is miR‐34a a Well‐equipped Swordsman to Conquer Temple of Molecular Oncology?
Farooqı, A. A., Fayyaz, S., Shatynska‐Mytsyk, I., Javed, Z., Jabeen, S., Yaylım, İ., Gasparri, M. L., & Panici, P. B. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12634 · Cited by 37
MicroRNA-targeting therapeutics for hepatitis C
Baek, J., Kang, S., & Min, H. (2014) · Archives of pharmacal research · doi:10.1007/s12272-013-0318-9 · Cited by 35
CRISPR therapy towards an HIV cure
Herrera-Carrillo, E., Gao, Z., & Berkhout, B. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz021 · Cited by 33
Cavalcante, P., Mizrachi, T., Barzago, C., Scandiffio, L., Bortone, F., Bonanno, S., Frangiamore, R., Mantegazza, R., Bernasconi, P., Brenner, T., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104388 · Cited by 28
Zhang, S., Yue, W., Xie, Y., Liu, L.-Z., Li, S., Dang, W., Xin, S., Li, Y., Zhai, X., Cao, P., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7316 · Cited by 28
Leichter, A. L., Purcell, R. V., Sullivan, M. J., Eccles, M. R., & Chatterjee, A. (2015) · GigaScience · doi:10.1186/s13742-015-0099-9 · Cited by 27
Lan, C., Peng, H., McGowan, E. M., Hutvágner, G., & Li, J. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0434-y · Cited by 27
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
Beierlein, J. M., McNamee, L. M., & Ledley, F. D. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.017 · Cited by 26
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial
Waddington‐Cruz, M., Ackermann, E. J., Polydefkis, M. J., et al. (2018) · Amyloid · doi:10.1080/13506129.2018.1503593 · Cited by 26
Azuma, K., Nakashiro, K., Sasaki, T., Goda, H., Onodera, J., Tanji, N., Yokoyama, M., & Hamakawa, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.024 · Cited by 22
DNA as Therapeutics; an Update
Saraswat, P., Soni, R., Bhandari, A., & Nagori, B. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.58169 · Cited by 22
le Sage, C., Lawo, S., & Cross, B. C. S. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219883621 · Cited by 22
RNA interference for viral infections.
Blake, S., Bokhari, F., & McMillan, N. (2012) · Current Drug Targets · doi:10.2174/138945012803530161 · Cited by 20
Liu, B., & Montgomery, S. B. (2019) · Human Genetics · doi:10.1007/s00439-019-02044-2 · Cited by 20
Iwama, H., Murao, K., Imachi, H., & Ishida, T. (2010) · Molecular Biology and Evolution · doi:10.1093/molbev/msq231 · Cited by 19
Gene Therapy in Infants with Severe Combined Immunodeficiency
Otsu, M., & Candotti, F. (2002) · BioDrugs · doi:10.2165/00063030-200216040-00001 · Cited by 15
Adams, D., Coelho, T., Conceição, I. M., Waddington‐Cruz, M., Schmidt, H., Buades, J., Campistol, J. M., Pouget, J., Berk, J. L., Polydefkis, M. J., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.s27.004 · Cited by 12
Regulation of cardiac stem cells by microRNAs: State-of-the-art
Gorabi, A. M., Bianconi, V., Pirro, M., Banach, M., & Sahebkar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109447 · Cited by 9
Empirical insights into the stochasticity of small RNA sequencing
Qin, L., Tuschl, T., & Singer, S. (2016) · Scientific Reports · doi:10.1038/srep24061 · Cited by 8
New Medications in the Treatment of Hereditary Transthyretin Amyloidosis
Walker, S. E. (2018) · Hospital Pharmacy · doi:10.1177/0018578718779757 · Cited by 4
Cited by
siRNA: Mechanism of action, challenges, and therapeutic approaches
Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174178 · Cited by 441
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Smart Nanocarriers for the Delivery of Nucleic Acid‐Based Therapeutics: A Comprehensive Review
Ramasamy, T., Munusamy, S., Ruttala, H. B., & Kim, J. O. (2021) · Biotechnology Journal · doi:10.1002/biot.201900408 · Cited by 76
Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113180119 · Cited by 43
Metadata
- Authors
- Bajan, S., & Hutvagner, G.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-01-07
- Volume
- 9
- Issue
- 1
- Pages
- 137
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3000595341
- Cited by
- 393
- References
- 203
- FWCI
- 16.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.